Pharmacyclics Incorporated (PCYC)
PCYC (NASDAQ:Drugs)
$84.70
-3.56
-4.03%
Today's Range: 84.62 - 88.72 |
PCYC Avg Daily Volume: 709,400
| Last Update: 06/19/13 - 4:00 PM EDT |
| Volume: 379,728 |
| YTD Performance: 50.90%
|
| Open: $88.52 |
| Previous Close: $88.26 |
| 52 Week Range: $41.37 -
$95.85 |
| Oustanding Shares: 72,783,040 |
| Market Cap: 6,345,953,258 |
6-Month Chart
TheStreet Ratings Grade for PCYC
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
4 |
4 |
4 |
4 |
| Moderate Buy |
1 |
1 |
0 |
0 |
| Hold |
6 |
6 |
7 |
7 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.18 |
2.18 |
2.27 |
2.27 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
73.15 |
|
| Price Earnings Comparisons: |
| PCYC |
Sector Avg. |
S&P 500 |
| 73.15 |
75.20 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-3.03%
|
114.07%
|
1,145.57%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
895.90 |
0.00 |
0.00 |
| Net Income |
0.00 |
-1.51 |
0.00 |
| EPS |
0.00 |
-1.19 |
0.00 |
| Earnings for PCYC: |
| EBITDA |
0.01B |
| Revenue |
0.08B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.05 |
$-0.18 |
$-0.48 |
$-0.73 |
| Number of Analysts |
6 |
8 |
9 |
10 |
| High Estimate |
$0.03 |
$0.35 |
$1.94 |
$1.39 |
| Low Estimate |
$-0.23 |
$-0.46 |
$-1.61 |
$-3.14 |
| Prior Year |
$-0.24 |
$1.02 |
$0.17 |
$-0.48 |
| Growth Rate (Year over Year) |
79.17% |
-117.52% |
-380.39% |
-52.73% |
Feb 15, 2013 | 7:43 AM EST
Shares of PCYC now seen reaching $90, accoridng to Credit Suisse. Estimates also increased, as Ibrutinib should drive growth. Outperfor...
Jan 15, 2013 | 8:07 AM EST
Shares of PCYC rated new Outperform, Credit Suisse said. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class...
Jan 14, 2013 | 8:49 AM EST
PCYC was downgraded to Neutral, Lazard Capital Markets said. Company lacks near-term catalysts.
| Jan 08, 2013 | 6:25 PM EST
It's encouraging now to see the S&P hold onto most of those post fiscal cliff gains.
By
Adam Feuerstein
Dec 07, 2012 | 6:00 AM EST
Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.
| Nov 30, 2012 | 3:13 PM EST
My list doubles in size.
Aug 02, 2012 | 7:45 AM EDT
PCYC was downgraded from Buy to Hold, Needham said. Valuation call.
Jul 13, 2012 | 7:56 AM EDT
PCYC was initiated with a Market Perform rating, Bernstein said. $51 price target. Valuation call, as the stock is up 300% year-to-date...
| Jul 03, 2012 | 12:04 PM EDT
These mid-caps are volatile, but a merger or major announcement could send them soaring.
| Jul 02, 2012 | 1:16 PM EDT
The weak ISM number will eventually matter, but for now, traders are focused on technical conditions.
